Obeidat Khaldun, Alsaud Arwa, Ashour Amr, Azrieh Bahjat, Abu-Tineh Mohammad, Mohamed Shehab Fareed, Yassin Mohamed A
Department of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Department of Medical Education, Hamad Medical Corporation, Department of Medical Oncology, NCCCR, Hamad Medical Corporation, Doha, Qatar.
Case Rep Oncol. 2019 Dec 9;12(3):913-917. doi: 10.1159/000504937. eCollection 2019 Sep-Dec.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by three phases: chronic, accelerated, and blast phase. However; first- and second-generation tyrosine kinase inhibitors are used for the treatment of CML with common and uncommon adverse events. Here, we report a 24-year-old male with CML in chronic phase started on imatinib as upfront medication who developed tremor and recovered spontenously after 3 years.
慢性髓性白血病（CML）是一种骨髓增殖性肿瘤，其特征为三个阶段：慢性期、加速期和急变期。然而，第一代和第二代酪氨酸激酶抑制剂被用于治疗CML，会出现常见和不常见的不良事件。在此，我们报告一名24岁处于慢性期的CML男性患者，初始用药为伊马替尼，用药后出现震颤，并在3年后自行恢复。
